Clinical Efficacy Evaluation of Serum PLA2R Combined with IgG4 Detection in Adult Idiopathic Membranous Nephropathy

Abstract

Abstract: Objective To investigate the early detection and diagnosis of the expression levels of serum M-type phosphatase A2 receptor (PLA2R) combined with renal tissue IgG4 in adult idiopathic membranous nephropathy, and to explore its significance. MethodForty-two adult patients with idiopathic membranous nephropathy admitted to Qingdao Shibei District Geriatric Hospital (Qingdao Shibei District People's Hospital) from May 2020 to May 2022 were selected as the observation group, while 34 patients with minimal lesions of kidney disease admitted during the same period were selected as control group A and 30 patients with membranous nephropathy were selected as control group B. The observation group was treated with cyclosporin A combined with glucocorticoid. The serum M-type phosphatase A2 receptor (PLA2R) and renal tissue IgG4 levels were compared in several groups of patients. ResultThere were no significant differences in gender, age, disease duration, 24-hour urine protein, serum albumin, blood creatinine, and blood urea levels among the three groups of patients (P>0.05). Compared with control group A and control group B, the observation group had higher PLA2R measurement values and higher positive rates of IgG4 measurement in renal tissue. The difference between the groups was statistically significant (P<0.05). There was no statistically significant difference (P>0.05) in the measurement results of BPLA2R and IgG4 in renal tissue between control group A and control group. The PLA2R measurement value in the observation group was lower after treatment compared to before treatment, and the difference between the groups was statistically significant (P<0.05). Conclusions erum M-type phosphatase A2 receptor (PLA2R) and renal tissue IgG4 show abnormal expression levels in adult patients with idiopathic membranous nephropathy, which is significantly different from that in healthy people and membranous lupus nephritis, which can provide reference for the diagnosis of the disease.

Key words: serum M-type phosphatase A2 receptor, IgG4 in renal tissue, adult idiopathic membranous nephropathy

CLC Number:

R692

BAO Mei-yan, JI Yan-xin. Clinical Efficacy Evaluation of Serum PLA2R Combined with IgG4 Detection in Adult Idiopathic Membranous Nephropathy[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(19): 170-173.

References

[1] 蒋真斌,蔡美顺,董葆,等.适合中国人的抗磷脂酶A2受体抗体临界值的界定[J].中华肾脏病杂志,2020,36(5):379-384.
[2] 史玉洁,翁亚菡.膜性肾病的病理学特点及诊断[J].中国临床医生杂志,2019,47(9):1020-1023.
[3] 金娟,任燕,龚建光,等.s抗磷脂酶A2受体抗体在特发性膜性肾病中的应用价值及与临床相关性探讨[J].中华全科医学,2020,18(2):208-212.
[4] 郭亚玲,张海峰,吴雪平.特发性膜性肾病临床病理分析[J].齐齐哈尔医学院学报,2020,41(1):44-47.
[5] 李彤,韦翠美,齐东丽,等.特发性膜性肾病患者肾小球硬化与肾脏预后的相关性分析[J].国际泌尿系统杂志,2020,40(5):847-852.
[6] 蔡小凡,张晓丹,钟逸斐,等.肾病综合征特发性膜性肾病患者临床病理特征与肾功能的相关性[J].中国中西医结合肾病杂志,2020,21(4):317-320.
[7] 谢琼虹,陈瑞颖,薛骏,等.原发性膜性肾病(PMN)的诊治进展[J].复旦学报(医学版),2020,47(4):615-621.
[8] PECHLIVANI N, KEARNEY K J, AJJAN R A.Fibrinogen and antifibrinolytic proteins: interactions and future therapeutics[J].Int J Mol Sci,2021,22(22):12537.
[9] 郭宁,王娜,吕国庆.特发性膜性肾病磷脂酶A2受体抗原表达情况与临床特征、预后的关系[J].中国医师杂志,2020,22(7):1026-1029.
[10] 吴冕,王凉.特发性膜性肾病相关靶抗原及补体途径研究进展[J].医学综述,2020,26(14):2733-2737.
[11] 陈琪,闵晶晶,施占琴,等.单中心特发性膜性肾病免疫抑制治疗与保守治疗的短期疗效及不良反应观察[J].重庆医学,2020,49(5):722-727.
[12] 郭永力,穆永芳,管仁苹,等.MMF联合泼尼松治疗成人特发性膜性肾病的疗效及安全性研究[J].现代生物医学进展,2020,20(13):2597-2600,2580.
[13] 罗先荣,彭家清.特发性膜性肾病诊疗中磷脂酶A2受体的研究进展[J].重庆医学,2020,49(1):160-165.
[14] WANG W L, GUO D H.Evaluation study on off-label use of rituximab in membranous nephropathy[J]. Chin J Drug Appl Monit,2022,19(3):150-154.
[15] 陆小云,张焕新.急性白血病血清sICAM-1、IL-10和TNF-α水平变化及临床意义[J].临床血液学杂志,2020,33(11):762-766.
[16] KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES( KDIGO) GLOMERULAR DISEASES WORK GROUP.KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J].Kidney Int,2021,100(4S):S1-S276.
[17] 耿秀蓉,刘真,施春晓,等.早期特发性膜性肾病患者血清IL-2、IL–10、TNF–α和FN–γ水平及临床意义[J].临床血液学杂志,2022,35(4):244-246.
[18] 黄雯静,舒婷婷,莫微微,等.抗PLA2R-Ab滴度用于成人特发性膜性肾病鉴别诊断临床价值及最佳cut-off值研究[J].中国中西医结合肾病杂志,2022,(12):1079-1081.
[19] 夏璁,张文,何灵芝,等.不同病理分期成人特发性膜性肾病患者免疫抑制治疗疗效及预后分析[J].中国中西医结合肾病杂志,2020,21(7):589-592.
[20] 林秀日,林栩.特发性膜性肾病相关诊断生物标志物的研究进展[J].右江医学,2020,48(9):641-645.